FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904219160> ?p ?o ?g. }

• W2904219160 endingPage "523" @default.
• W2904219160 startingPage "516" @default.
• W2904219160 abstract "Leishmaniasis is an expanding health threat worldwide complicated by the absence of an effective vaccine. We investigated transcutaneous immunization (TCI) as a needle-free immunization route which exploits the abundance of antigen presenting cells in the skin to induce both mucosal and systemic immunity. Leishmania (L.) major soluble antigens (SLA) or recombinant Leishmania homolog of receptors for activated C-kinase (rLACK) antigens were delivered transcutaneously together with cholera toxin (CT), to BALB/c mice. Mice were immunized at weeks 1, 4, and 7 with PBS, CT, SLA/CT or rLACK/CT. Two weeks after the final boost, antigen-specific IgG titers, IFN-γ ELISpot, and cytokine levels were assessed in half of the mice and the remainder were challenged with an intradermal (ear) injection of 5 × 104 L. major metacyclic parasites. Mice were monitored weekly and sacrificed after 7 weeks to assess the parasite burden and to study the ear lesion immunohistopathology. Our results show that TCI with SLA or rLACK yielded high levels of anti-SLA, anti-rLACK and anti-CT IgG antibodies. A Th1-type of immune response was demonstrated with a high frequency of IFN-γ secreting cells, high levels of IFN-γ production, and lower levels of IL-10 resulting in a high IFN-γ/IL-10 ratio in mice immunized with SLA/CT or rLACK/CT. After parasite challenge, rLACK immunization was not associated with protection. In addition, SLA/CT immunized mice had larger ear lesions and an increased parasite load in the ear. Immunohistochemistry of ear biopsies stained for nitric oxide synthase revealed that staining intensity was diminished in the SLA/CT group compared to the control group. This finding suggested that less parasite killing occurred at the site of the infection. In conclusion, despite a strong Th1 type profile induced by TCI, exacerbation of infection occurred after challenge with L. major. This also correlated with low induction of nitric oxide." @default.
• W2904219160 created "2018-12-22" @default.
• W2904219160 creator A5005601710 @default.
• W2904219160 creator A5007536314 @default.
• W2904219160 creator A5038142202 @default.
• W2904219160 creator A5043348935 @default.
• W2904219160 creator A5047715241 @default.
• W2904219160 creator A5072305151 @default.
• W2904219160 creator A5078546000 @default.
• W2904219160 date "2019-01-01" @default.
• W2904219160 modified "2023-09-23" @default.
• W2904219160 title "Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge" @default.
• W2904219160 cites W1005323415 @default.
• W2904219160 cites W1490606958 @default.
• W2904219160 cites W1559734595 @default.
• W2904219160 cites W1601816956 @default.
• W2904219160 cites W1608119507 @default.
• W2904219160 cites W1609492724 @default.
• W2904219160 cites W1625990430 @default.
• W2904219160 cites W1963838923 @default.
• W2904219160 cites W1976175950 @default.
• W2904219160 cites W1987366735 @default.
• W2904219160 cites W1987603241 @default.
• W2904219160 cites W1991484350 @default.
• W2904219160 cites W1994879603 @default.
• W2904219160 cites W2002204067 @default.
• W2904219160 cites W2007063916 @default.
• W2904219160 cites W2009210209 @default.
• W2904219160 cites W2009685269 @default.
• W2904219160 cites W2011237115 @default.
• W2904219160 cites W2012518985 @default.
• W2904219160 cites W2022851527 @default.
• W2904219160 cites W2035430351 @default.
• W2904219160 cites W2035474364 @default.
• W2904219160 cites W2041437559 @default.
• W2904219160 cites W2043832228 @default.
• W2904219160 cites W2064777681 @default.
• W2904219160 cites W2073023385 @default.
• W2904219160 cites W2074644098 @default.
• W2904219160 cites W2078216090 @default.
• W2904219160 cites W2088368520 @default.
• W2904219160 cites W2091812042 @default.
• W2904219160 cites W2094028486 @default.
• W2904219160 cites W2096195586 @default.
• W2904219160 cites W2103948525 @default.
• W2904219160 cites W2115569719 @default.
• W2904219160 cites W2116394003 @default.
• W2904219160 cites W2117451755 @default.
• W2904219160 cites W2123328954 @default.
• W2904219160 cites W2124601850 @default.
• W2904219160 cites W2134355978 @default.
• W2904219160 cites W2135921009 @default.
• W2904219160 cites W2141360780 @default.
• W2904219160 cites W2142668016 @default.
• W2904219160 cites W2144763053 @default.
• W2904219160 cites W2146592112 @default.
• W2904219160 cites W2150185307 @default.
• W2904219160 cites W2151440062 @default.
• W2904219160 cites W2153930422 @default.
• W2904219160 cites W2157261600 @default.
• W2904219160 cites W2161130214 @default.
• W2904219160 cites W2165340588 @default.
• W2904219160 cites W2166902572 @default.
• W2904219160 cites W2169666849 @default.
• W2904219160 cites W2170122868 @default.
• W2904219160 cites W2228046611 @default.
• W2904219160 cites W2326904022 @default.
• W2904219160 cites W2336587604 @default.
• W2904219160 cites W4313316606 @default.
• W2904219160 doi "https://doi.org/10.1016/j.vaccine.2018.11.052" @default.
• W2904219160 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30528328" @default.
• W2904219160 hasPublicationYear "2019" @default.
• W2904219160 type Work @default.
• W2904219160 sameAs 2904219160 @default.
• W2904219160 citedByCount "4" @default.
• W2904219160 countsByYear W29042191602020 @default.
• W2904219160 countsByYear W29042191602022 @default.
• W2904219160 crossrefType "journal-article" @default.
• W2904219160 hasAuthorship W2904219160A5005601710 @default.
• W2904219160 hasAuthorship W2904219160A5007536314 @default.
• W2904219160 hasAuthorship W2904219160A5038142202 @default.
• W2904219160 hasAuthorship W2904219160A5043348935 @default.
• W2904219160 hasAuthorship W2904219160A5047715241 @default.
• W2904219160 hasAuthorship W2904219160A5072305151 @default.
• W2904219160 hasAuthorship W2904219160A5078546000 @default.
• W2904219160 hasBestOaLocation W29042191601 @default.
• W2904219160 hasConcept C136764020 @default.
• W2904219160 hasConcept C147483822 @default.
• W2904219160 hasConcept C159654299 @default.
• W2904219160 hasConcept C203014093 @default.
• W2904219160 hasConcept C2776090121 @default.
• W2904219160 hasConcept C2779053233 @default.
• W2904219160 hasConcept C2780599195 @default.
• W2904219160 hasConcept C2780801004 @default.
• W2904219160 hasConcept C2781092759 @default.
• W2904219160 hasConcept C41008148 @default.
• W2904219160 hasConcept C71924100 @default.
• W2904219160 hasConcept C71928629 @default.

• next